GB864100A — Therapeutic pencillin compositions and the preparation thereof
Assigned to Pfizer Inc · Expires 1961-03-29 · 65y expired
What this patent protects
Injectable suspensions comprise an aqueous suspension of a water-insoluble salt of penicillin and 0.5 to 10% of choline or a water-soluble derivative thereof. About 3 to 10% of urea or a derivative, 1 to 5% of a parenterally acceptable suspending agent and about 0.25 to 5% (base…
USPTO Abstract
Injectable suspensions comprise an aqueous suspension of a water-insoluble salt of penicillin and 0.5 to 10% of choline or a water-soluble derivative thereof. About 3 to 10% of urea or a derivative, 1 to 5% of a parenterally acceptable suspending agent and about 0.25 to 5% (based on the weight of the penicillin salt) of a parenterally acceptable buffer. Preservatives may also be added. The penicillin salt may be that with procaine, dibenzylethylenediamine, N - benzyl - N1 - (3 - ethoxy - 4 - hydroxy)-benzyl ethylenediamine, 2-chloroprocaine and N,N1 - di - (4 - methoxybenzyl) ethylene diamine. The choline derivative may be the chloride, dihydrogen tartrate, dihydrogen citrate or chloride carbamate. Examples of urea derivatives are thiocarbamide, carbamyl chloride, urea nitrate, thiomethane, lower (up to four carbon atoms) alkyl carbamates.
Drugs covered by this patent
- Abilify (aripiprazole) · Generic (originally Otsuka/BMS)
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.